PPA
CRSP icon

Parametric Portfolio Associates’s CRISPR Therapeutics CRSP Stock Holding History

Parametric Portfolio Associates’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.93M Buy
30,725
+5,696
+23% +$358K ﹤0.01% 2436
2021
Q4 		$1.9M Buy
25,029
+10,840
+76% +$947K ﹤0.01% 2466
2021
Q3 		$1.59M Sell
14,189
-458
-3% -$57.5K ﹤0.01% 2558
2021
Q2 		$2.37M Buy
+14,647
New +$1.78M ﹤0.01% 2335

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Parametric Portfolio Associates's CRSP Position: Q1 2022 in Review

Parametric Portfolio Associates increased its CRISPR Therapeutics (CRSP) stake by 23% in Q1 2022, buying an estimated $358K and bringing the position to 30,725 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2436.

Parametric Portfolio Associates first reported a position in CRSP in Q2 2021 and has held it in 4 quarters since. The position peaked at $2.37M in Q2 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

  • Parametric Portfolio Associates held 30,725 shares of CRISPR Therapeutics worth $1.93M as of Q1 2022.
  • Parametric Portfolio Associates bought 5,696 CRISPR Therapeutics shares in Q1 2022, an estimated $358K.
  • CRISPR Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2436 holding.
  • Parametric Portfolio Associates first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 4 quarters since.
  • Parametric Portfolio Associates's CRISPR Therapeutics position peaked at $2.37M in Q2 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.